Zoom Stroke Solution Shows Continued Efficacy in Treating Distal Occlusions of Ischemic Stroke

Author(s):

For patients with MCA M2 occlusions, use of the Zoom Stroke Solution resulted in significant decreases in National Institutes of Health Stroke Scale scores and no reported perforations or other reperfusion–catheter-related complications.

Collin Torok, MD

Findings from a study presented by author Collin Torok, MD, neurointerventional surgeon, Midwest Radiology, at the World Federation of Interventional and Therapeutic Neuroradiology 2022 Annual Meeting highlighted the safety and efficacy of the Zoom Stroke Solution to help patients with middle cerebral artery occlusions achieve reperfusion success.¹

In the independent, single-center study, 92.7% and 63.4% of the 41-patient cohort who used the platform achieved 2b/3 reperfusion and 2c/3 reperfusion, respectively, based on the thrombolysis in cerebral infarction (TICI) scale. From arrival to discharge, median scores on National Institute of Health Stroke Scale significantly decreased from 10.5 (IQR, 7.0-14.5) to 1.5 (IQR, 0-6.0; P <.001).

"More and more physicians are treating distal vessel occlusions despite their location in the brain—which can be more challenging to reach than other types of occlusions—resulting in a meaningful clinical impact. We are pleased to see the results from this single-center experience demonstrating the unique capabilities of the Zoom Reperfusion Catheters for the treatment of MCA M2 segment occlusions,” Daniel Davis, president and chief operating officer, Imperative Care, the designer of the treatment, said in a statement.¹

Imperative’s Zoom Stroke Solution is a complete stroke system built for clot removal that includes the Zoom 88 Large Distal Platform for neurovascular access, 4 vessel-matched Zoom Aspiration Catheters, the Zoom Pump, the Zoom POD, and other accessories. All Zoom catheters are designed with the TRX Tip which provides 15% greater clot engagement area at the tip of the catheter and are designed to enable smooth tracking through challenging vasculature.

The stroke system demonstrated safety as well, with no documented perforations or other reperfusion catheter-related complications. Notably, there was one instance (2.4%) of symptomatic intracranial hemorrhage in the study cohort. Overall, the median time from access to first aspiration attempt was 10 minutes (IQR, 6.6-16.5) and median time from access to final reperfusion was 21.5 minutes (IQR, 16.0-31.8).

Torok said in a statement that “distal vessel occlusions are considered the next frontier in mechanical thrombectomy for stroke treatment. The data from this study offer additional clinical evidence that aspiration thrombectomy using the Zoom Stroke Solution is both safe and effective for occlusions in the MCA M2 segment. Furthermore, Zoom 88 provides an excellent intracranial access catheter platform for distal occlusions. Even in the most tortuous cases, we have more than halved our procedural times with rapid initial and repeat passes to the distal circulation as needed."¹

Recently, in late July, several real-world analyses evaluating the Zoom Stroke Solution were presented at the 2022 Society of Neurointerventional Surgery Annual Meeting. The first, presented by James Milburn, MD, demonstrated that intracranial guide catheter placement in the petrous internal carotid artery (ICA) segment or further distal vs placement in the cervical ICA segment or more proximal were associated with a better rate of at least 2C reperfusion on TICI (82.7% vs 60.0%; P = .019), and a better first-pass effect (51.9% vs 27.5%; P = .021). Additionally, access time to final recanalization was significantly shorter in patients with intracranial guide catheter placement (23.8 minutes) compared with patients who received proximal guide catheter placement (33.9 minutes; P = .011).

The second study evaluated the effect of intracranial flow parameters using the stroke platform for aspiration thrombectomy. All told, investigators observed a 67% flow reduction in the MCA when a Zoom 88 access catheter was positioned distal to the posterior communicating artery and proximal to the carotid terminus. This flow reduction was significantly greater when compared with the 54% reduction achieved with an inflated balloon guide catheter positioned in the proximal ICA.²

REFERENCES
1. Imperative Care announces positive new data underscoring the safety and efficacy of the Zoom Stroke Solution to treat distal occlusions in ischemic stroke patients. News release. Imperative Care. August 24, 2022. Accessed August 25, 2022. https://www.businesswire.com/news/home/20220824005294/en/Imperative-Care-Announces-Positive-New-Data-Underscoring-the-Safety-and-Efficacy-of-the-Zoom-Stroke-Solution-to-Treat-Distal-Occlusions-in-Ischemic-Stroke-Patients
2. Imperative Care announces positive real-world data showing that the Zoom Stroke Solution achieved superior procedure outcomes with lower cost in ischemic stroke patients. News release. Imperative Care. July 26, 2022. Accessed August 25, 2022. https://www.businesswire.com/news/home/20220726005064/en/Imperative-Care-Announces-Positive-Real-World-Data-Showing-that-the-Zoom-Stroke-Solution-Achieved-Superior-Procedure-Outcomes-with-Lower-Cost-in-Ischemic-Stroke-Patients